Market Cap | 136.75M | P/E | - | EPS this Y | 8.30% | Ern Qtrly Grth | - |
Income | -25.91M | Forward P/E | -4.32 | EPS next Y | -22.70% | 50D Avg Chg | 4.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 33.00% |
Dividend | N/A | Price/Book | 1.21 | EPS next 5Y | - | 52W High Chg | -22.00% |
Recommedations | 2.00 | Quick Ratio | 13.96 | Shares Outstanding | 125.76M | 52W Low Chg | 116.00% |
Insider Own | 0.06% | ROA | -19.68% | Shares Float | 117.92M | Beta | 1.20 |
Inst Own | 27.43% | ROE | -28.01% | Shares Shorted/Prior | 13.18M/12.86M | Price | 1.08 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 958,264 | Target Price | 5.50 |
Oper. Margin | - | Earnings Date | Nov 11 | Volume | 450,656 | Change | -1.82% |
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
Ascendiant Capital | Buy | Sep 11, 24 |
HC Wainwright & Co. | Buy | Aug 12, 24 |
HC Wainwright & Co. | Buy | Jun 28, 24 |
Cantor Fitzgerald | Overweight | Jun 20, 24 |
Ascendiant Capital | Buy | Jun 6, 24 |
Cantor Fitzgerald | Overweight | May 14, 24 |
HC Wainwright & Co. | Buy | May 13, 24 |
HC Wainwright & Co. | Buy | Apr 16, 24 |
HC Wainwright & Co. | Buy | Apr 2, 24 |